These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Lenalidomide in multiple myeloma. Thomas SK; Richards TA; Weber DM Best Pract Res Clin Haematol; 2007 Dec; 20(4):717-35. PubMed ID: 18070715 [TBL] [Abstract][Full Text] [Related]
3. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide. Richardson P Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100 [TBL] [Abstract][Full Text] [Related]
4. Novel agents for relapsed and/or refractory multiple myeloma. Thomas SK; Richards TA; Weber DM Cancer J; 2009; 15(6):485-93. PubMed ID: 20010168 [TBL] [Abstract][Full Text] [Related]
5. Lenalidomide in the treatment of multiple myeloma: a review. Armoiry X; Aulagner G; Facon T J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408 [TBL] [Abstract][Full Text] [Related]
6. New drugs for myeloma. Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058 [TBL] [Abstract][Full Text] [Related]
7. Lenalidomide and its role in the management of multiple myeloma. Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796 [TBL] [Abstract][Full Text] [Related]
9. Bortezomib in the front-line treatment of multiple myeloma. Richardson PG; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Munshi N; Anderson KC Expert Rev Anticancer Ther; 2008 Jul; 8(7):1053-72. PubMed ID: 18588451 [TBL] [Abstract][Full Text] [Related]
10. Management of multiple myeloma with bortezomib: experts review the data and debate the issues. Dicato M; Boccadoro M; Cavenagh J; Harousseau JL; Ludwig H; San Miguel J; Sonneveld P Oncology; 2006; 70(6):474-82. PubMed ID: 17283449 [TBL] [Abstract][Full Text] [Related]
11. Treatment options for relapsed and refractory multiple myeloma. Lonial S; Mitsiades CS; Richardson PG Clin Cancer Res; 2011 Mar; 17(6):1264-77. PubMed ID: 21411442 [TBL] [Abstract][Full Text] [Related]
12. Pomalidomide in the treatment of relapsed multiple myeloma. Forsberg PA; Mark TM Future Oncol; 2013 Jul; 9(7):939-48. PubMed ID: 23837756 [TBL] [Abstract][Full Text] [Related]
13. Thalidomide in the treatment of multiple myeloma. Kastritis E; Dimopoulos MA Best Pract Res Clin Haematol; 2007 Dec; 20(4):681-99. PubMed ID: 18070713 [TBL] [Abstract][Full Text] [Related]
19. [Effects of bortezomib at different doses in combination with dexamethasone in treatment of relapsed or refractory multiple myeloma: a comparative study]. Bao L; Lu XJ; Zhang XH; Huang XJ Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(26):1829-31. PubMed ID: 19040018 [TBL] [Abstract][Full Text] [Related]
20. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium. Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]